Magic mushroom compound tested as opioid addiction aid
NCT ID NCT04161066
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 20 times
Summary
This early-stage study tests whether adding psilocybin (the active ingredient in magic mushrooms) to standard buprenorphine/naloxone treatment is safe for people with opioid use disorder. Ten adults on stable medication will receive two doses of psilocybin while being monitored for side effects, withdrawal, and cravings. The goal is to see if psilocybin can help improve treatment outcomes without causing harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Conditions
Explore the condition pages connected to this study.